Breast Cancer
Conditions
Brief summary
The investigators are doing this study to determine if there are body composition changes after a 12-week exercise program in breast cancer patients and determine what factors contribute to sustained physical activity after the 12-week exercise program intervention.
Detailed description
The study is enrolling breast cancer patients up to 2 years after their diagnosis in a 12-week exercise program. The participants will either participate in: Group 1-participating in an exercise program with biometric evaluations or Group 2-biometric evaluations but not participating in the exercise program. At the end of the 12-week exercise program, participants in Group 1 will be randomized to either: a) continuing with exercise group classes or b) continuing with exercise individual classes. Both Group 1a and 1b participants will be followed for the remainder of the year and be evaluated for continued physical activity. All Group study participants' biometrics will be assessed at baseline and at the end of 12-weeks, with continued annual medical review follow-up for a total of 5 years.
Interventions
OTHERExercise
First Intervention 12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students Second Intervention- 12-week exercise program, 2 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific. Group Fitness Classes
Sponsors
University of Hawaii
Rehabilitation Hospital of the Pacific
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Participants choose the initial intervention (12-week exercise program (Group1) vs monitoring (Group2)).
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* New diagnosis of breast cancer (within the past 2 years, any subtype, stage I-III) * Can be undergoing neo/adjuvant treatment (surgery, chemotherapy, radiation or endocrine therapy) * Participant is willing and able to comply with the protocol for the duration of the study including undergoing scheduled exercise sessions, completing questionnaires and biometric/biomarker studies * Participant must be able to lie flat on their back for up to 10 minutes * Participant must be able to stand without aid for at least 2 minutes
Exclusion criteria
* Participant with breast cancer recurrence * Metastatic breast cancer * Uncontrolled psychiatric disorder that can affect self-assessment * Pregnant patient * Participants with any internal artifact (e.g. pacemakers, internal fixation, arthroplasty) or other physical impairment that would alter the body composition assessment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fat mass | 1 day | Measure fat mass (arms, legs, trunk and total) in kg using Dual energy X-ray absorptiometry (DXA) data |
| Isometric peak torque | 1 day | Measure the peak torque value generated during isometric knee extension/flexion movement evaluation at 60 degrees will be assessed with the HUMAC NORM device |
| Lean mass | 1 day | Measure lean mass (arms, legs, trunk and total) in kg using Dual energy X-ray absorptiometry (DXA) data |
| Bone mass | 1 day | Measure bone mass (arms, legs, trunk and total) in kg using Dual energy X-ray absorptiometry (DXA) data |
| Waist to Hip ratio (WHR) from manual tape measurement | 1 day | Manual physical anthropometry of waist and hip circumferences |
| Automatic 3D optical (3DO) scan measurement: girth measurement | 1 day | Automated 3DO measurements generate the following: girth in cm measurements across the whole body |
| Muscle Function | 1 day | Measure the peak torque value generated during isometric knee extension/flexion movement evaluation at 60 degrees will be assessed with the HUMAC NORM device |
| Percent fat | 1 day | Percent fat (arms, legs, trunk and total) using Dual energy X-ray absorptiometry (DXA) data |
| Automatic 3D optical (3DO) scan measurement: length measurement | 1 day | Automated 3DO measurements generate the following: length in cm measurements across the whole body |
| Automatic 3D optical (3DO) scan measurement: volume measurement | 1 day | Automated 3DO measurements generate the following: volume in cm measurements across the whole body |
| Bone Mineral Density (spine and total) using Dual energy X-ray absorptiometry (DXA) data | 1 day | Bone Mineral Density (spine and total) using Dual energy X-ray absorptiometry (DXA) data |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Recurrence Free Survival | 5 years | obtained from last physician note |
| BIBCQ-Body Image After Breast Cancer questionnaire | 5 years | 45 items |
| BFI-Brief Fatigue Innovatory questionnaire | 5 years | 9 items |
| PHQ-9- Patient Health (Depression) questionnaire | 5 years | 9 items |
| FACT-G-Functional Assessment of Cancer Therapy-General (Comorbidities)questionnaire | 5 years | 27 items |
| Diet History Questionnaire II | 5 years | Self-reported energy intake, measured as kcal/day |
| Biomarkers | 5 years | Adipokines: leptin, HMW-high molecular weight adiponectin, PAI1-plasminogen activator inhibitor Cytokines \& Inflammation: TNF-tumor necrosis factor α, IL-interleukin 1β, IL2, IL4, IL5, IL6, IL8, IL10, interferon, CRP-C reactive protein, uric acid, cortisol Insulin Resistance \& IGFs: glucose, insulin, Hb-hemoglobin A1C, IGF-insulin growth factor 1, IGFBP-insulin like growth factor binding protein 1-3 Sex Steroid Hormones: total estradiol \& estrone, total testosterone, SHBG-sex hormone-binding globulin (for free estradiol and free testosterone will be derived) Lipid Profile \& Lipid-soluble Micronutrients: TG-triglycerides , total cholesterol, HDLC-high density lipoprotein cholesterol , free fatty acids, lycopene, 25OH-vitamin D3, alpha-tocopherol Liver Enzymes: ALT-alanine aminotransferase Neuropeptides \& Gut Hormones: ghrelin MOTS-mitochondrial derived peptide-c |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJami Fukui, MD
University of Hawaii Cancer Research Center
Outcome results
None listed